Emerging Markets Ajanta Pharma has a broad footprint in emerging markets across Africa, South East Asia, West Asia, and the CIS with a wide range of therapeutic areas, presenting opportunities to expand distribution partnerships, co-promotion, and market-entry collaborations in high-growth regions.

Strong US Generic Presence With 49 ANDA approvals already commercialised and plans to file 8–12 new ANDAs annually, there is a solid pipeline to leverage for US market expansion through strategic distributor deals, licensing, or direct sales of generic formulations.

FDA-Approved Facilities Flagship manufacturing facilities at Paithan and Dahej are US FDA approved, signaling reliability for partner manufacturing, contract development and manufacturing (CDMO) opportunities, as well as potential for co-manufacturing of new generic products.

Therapeutic Diversification Recent entry into nephrology and gynecology, along with leadership in cardiology, dermatology, ophthalmology, and pain management, creates cross-sell opportunities for bundled portfolio solutions and collaboration with specialty distributors and clinics.

R&D and Digital Edge A large R&D team and use of modern tech stack (cloud, collaboration tools, AI assistance) indicate potential for partner-focused product development programs, patient support services, and digital engagement initiatives to drive uptake and adherence.